secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0001628280-24-039221
Event type: regulatory
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics regains Nasdaq compliance on market value standard; matter closed
--------------------------------------------------------------------------------

- Received written confirmation from Nasdaq on Sept 3, 2024 that market value exceeded $35M for 10 consecutive trading days.
- Regains compliance with Nasdaq Listing Rule 5550(b)(2) (Market Value of Listed Securities Standard).
- Previously received notice on May 20, 2024 for non-compliance with Stockholders' Equity Requirement.
- Compliance regained resolves the deficiency; no further Nasdaq action required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024039221/0001628280-24-039221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024039221/avtx-20240903.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-039221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer